8-K: Ligand Pharmaceuticals Reports Strong Q1 2024 Results Driven by Royalty Portfolio and Strategic Investments

Ligand Pharmaceuticals announced robust first-quarter financial results for 2024, fueled by its diverse royalty portfolio and strategic investments, while also reaffirming its full-year guidance.

Summary

• Ligand Pharmaceuticals reported total revenues of $31.0 million for Q1 2024, compared to $44.0 million in Q1 2023.
• Royalty revenues increased to $19.1 million, up from $17.6 million in the same period last year, driven by products like Kyprolis, RYLAZE, VAXNEUVANCE, and FILSPARI, offset by a decline in EVOMELA.
• Captisol sales were $9.2 million, down from $10.6 million in Q1 2023 due to the timing of customer orders.
• Contract revenue was $2.7 million, compared to $15.7 million in the prior year, which included a $15.3 million milestone payment from Travere Therapeutics.
• Net income from continuing operations was $86.1 million, or $4.75 per diluted share, compared to $43.6 million, or $2.43 per diluted share, in Q1 2023, largely due to a $60.0 million gain from the sale of Viking Therapeutics stock.
• Adjusted net income from continuing operations was $69.7 million, or $3.84 per diluted share, compared to $39.9 million, or $2.28 per diluted share, in the same period last year.
• Core adjusted net income, excluding the Viking Therapeutics stock sale, was $21.8 million, or $1.20 per diluted share, compared to $23.4 million, or $1.33 per diluted share, in Q1 2023.
• The company reaffirmed its 2024 financial guidance, projecting total revenues between $130 million and $142 million, with core adjusted earnings per diluted share between $4.25 and $4.75.

Sentiment

Score: 8

Explanation: The overall sentiment is highly positive due to strong financial results, the significant gain from the Viking Therapeutics stock sale, promising new partnerships, and positive regulatory developments. However, the decline in Captisol sales and the potential delay in the development of IV ganaxolone slightly temper the otherwise very positive sentiment.

Positives

• Strong royalty revenue growth driven by multiple products in the portfolio.
• Significant gain from the sale of Viking Therapeutics stock boosted net income.
• New royalty financing agreement with Agenus adds promising oncology assets to the portfolio.
• Upcoming commercial launch of ZELSUVMI by Pelthos Therapeutics.
• Positive regulatory developments for FILSPARI in both Europe and the U.S.

Negatives

• Decline in Captisol sales due to timing of customer orders.
• Lower contract revenue compared to the prior year, which included a significant milestone payment.
• Marinus Pharmaceuticals' Phase 3 RAISE trial for IV ganaxolone did not meet pre-defined stopping criteria at the interim analysis.

Risks

• Reliance on collaborative partners for milestone payments, royalties, and other revenue.
• Potential for partners to change development focus or not execute on sales and marketing plans.
• Uncertainty regarding regulatory approval and market acceptance of products under development.
• Competition in acquiring royalties and developing technology platforms.
• Dependence on a single-source supplier for Captisol.
• Potential challenges in protecting intellectual property.
• Delays in clinical trials or issues with trial designs.
• Risks associated with integrating acquisitions.
• Potential impact of general economic conditions, including war, conflict, or epidemic diseases.
• Ongoing or future litigation could expose Ligand to significant liabilities.

Future Outlook

Ligand reaffirmed its 2024 financial guidance, projecting total revenues between $130 million and $142 million, with core adjusted earnings per diluted share between $4.25 and $4.75. This guidance excludes the $60 million gain from short-term investments on the sale of Viking Therapeutics stock.

Management Comments

• We are pleased to report another quarter of strong financial results driven by the performance of our commercial royalty portfolio.
• Simultaneously, we continue to build our portfolio of development stage royalty assets to deliver future growth.
• We continue to originate a robust pipeline of royalty opportunities with our proactive business development efforts.
• This is evidenced by our most recent royalty financing agreement with Agenus which will add several new late stage oncology assets to our portfolio.
• As we look ahead to the near term, we have several important catalysts in our existing portfolio in 2024.
• This includes Verona Pharmas ensifentrine and Mercks V116, both of which have been assigned PDUFA dates in June, top-line Phase 3 data on Takedas soticlestat, expected in the third quarter, and the commercial launch of ZELSUVMI, a much-needed treatment for molluscum contagiosum, in late 2024.

Industry Context

Ligand's announcement showcases its continued success in the biopharmaceutical royalty acquisition and licensing space. The company's focus on diversifying its portfolio and investing in late-stage assets aligns with industry trends of seeking external innovation and leveraging partnerships to drive growth. The deal with Agenus further expands Ligand's presence in the growing oncology market.

Comparison to Industry Standards

• Ligand's royalty revenue growth of 8.5% year-over-year is a positive sign, although it is difficult to directly compare to specific companies due to the unique nature of each royalty portfolio.
• Ligand's business model is similar to other royalty aggregators like Royalty Pharma (RPRX) and Healthcare Royalty Partners, which also acquire royalties on pharmaceutical products.
• Royalty Pharma, a major player in the industry, reported royalty receipts of $758 million in Q4 2023, significantly higher than Ligand's $19.1 million in Q1 2024, reflecting Royalty Pharma's larger scale and more mature portfolio.
• Ligand's focus on late-stage assets is a common strategy in the royalty space, as it reduces development risk and provides a faster path to revenue generation.
• Compared to traditional biotech companies, Ligand's business model is less reliant on internal R&D and carries lower development risk, but it is also dependent on the success of its partners' products.
• Ligand's Captisol business provides a unique technology platform that differentiates it from pure-play royalty companies and is used by major pharmaceutical companies like Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

Stakeholder Impact

• Shareholders may benefit from increased net income and potential future revenue growth from the expanded royalty portfolio.
• Employees may benefit from the company's growth and expansion, particularly with the launch of Pelthos Therapeutics and the commercialization of ZELSUVMI.
• Customers may benefit from the availability of new treatments like ZELSUVMI and FILSPARI.
• Suppliers, such as the Captisol supplier, may be impacted by fluctuations in demand.
• Creditors should be aware of the restrictions under Ligand's credit agreement.

Next Steps

• Commercial launch of ZELSUVMI by Pelthos Therapeutics in late 2024.
• Monitor progress of partners' clinical trials, including Verona Pharma's ensifentrine, Merck's V116, Takeda's soticlestat, and Viking Therapeutics' VK2809.
• Continue to pursue royalty acquisition opportunities and expand the portfolio.
• Assess future development of IV ganaxolone following review of the final RAISE trial results.
• Await FDA decision on Travere Therapeutics' sNDA for FILSPARI, with a PDUFA target action date of September 5, 2024.

Key Dates

Keywords

royalty financing, biopharmaceutical, Captisol, ZELSUVMI, molluscum contagiosum, oncology, IgA nephropathy, clinical trials, FDA approval, revenue growth, strategic investments, Agenus, Travere Therapeutics, Viking Therapeutics, Marinus Pharmaceuticals